Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ
4.03
-0.21 (-4.95%)
Closed
Oct 16, 2026
Day's Range
4.004.27
52 wk Range
4.009.94
Financial Statements - VNDA - Vanda Pharmaceuticals Inc.
Revenue
216.10M▲ 8.7%
Net Income
-220.47M▼ 1066.5%Net Margin -102.0%
EBITDA
-139.25M▼ 328.1%
Free Cash Flow
-110.44M▼ 579.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 216.10M | 198.77M | 192.64M | 254.38M | 268.68M | 248.16M |
| Cost of Goods | 13.04M | 11.31M | 14.79M | 24.28M | 25.62M | 23.36M |
| Gross Profit | 203.06M | 187.45M | 177.84M | 230.10M | 243.05M | 224.80M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -151.16M | -40.66M | -13.95M | 6.32M | 42.16M | 27.23M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 12.52M | 17.73M | 20.29M | 4.97M | 199K | 4.41M |
| Pre Tax Income | -138.64M | -22.92M | 6.33M | 11.30M | 42.36M | 31.65M |
| Income Tax | 81.82M | -4.02M | 3.83M | 5.02M | 9.21M | 8.31M |
| Net Income | -220.47M | -18.90M | 2.50M | 6.27M | 33.15M | 23.33M |
| EPS Basic | -3.74 | -0.33 | 0.04 | 0.11 | 0.6 | 0.43 |
| EPS Diluted | -3.74 | -0.33 | 0.04 | 0.11 | 0.58 | 0.42 |
| Basic Shares Outstanding | 58.93M | 58.14M | 57.38M | 56.46M | 55.54M | 54.42M |
| Diluted Shares Outstanding | 58.93M | 58.14M | 57.38M | 56.46M | 55.54M | 54.42M |
| Ebit | -151.16M | -40.66M | -13.95M | 6.32M | 42.16M | 27.23M |
| Ebitda | -139.25M | -32.52M | -10.94M | 9.06M | 45M | 30.10M |
| Net Income Continuous Operations | -220.47M | -18.90M | 2.50M | 6.27M | 33.15M | 23.33M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
